Venezuela's President Nicols Maduro appears to be counting on yet another miracle to save his citizens from COVID-19, promoting a secretive solution with no published scientific evidence he claims will conquer the new coronavirus.
Ten drops under the tongue every four hours and the miracle is done, Maduro said in a televised appearance on Sunday.
It's a powerful antiviral, very powerful, that neutralises the coronavirus. But his government has released no evidence. He even kept secret the name of the brilliant Venezuelan mind behind it, saying he needed to protect them.
Scientists at home and abroad remained skeptical.
The local National Academy of Medicine said it appeared be derived from the common herb thyme.
It's not the first time the Venezuelan leader has promoted a cure. In October, he notified the Pan American Health Organization that Venezuelan scientists discovered a molecule that nullifies the replication capacity of the new coronavirus.
He hasn't spoken of that development since. He's also promoted a special herbal tea he claims can fend off the virus and other ailments.
Other leaders too have embraced solutions dismissed by scientific studies. Former US President Donald Trump and Brazil's Jair Bolsonaro both stubbornly touted an antimalarial drug despite repeated studies finding it ineffective and possibly dangerous.
The new coronavirus hasn't hit Venezuela as hard as other South American countries such as Brazil, Ecuador and Peru, though many experts say that's likely because sanctions against Maduro's government have sharply limited travel there.
Maduro said the treatment, which he called carvativir, has been under testing for nine months among Venezuelans ill with the coronavirus. He said he plans to distribute it nationwide and to other nations as well.
Dr David Boulware, professor of medicine and an infectious diseases physician at the University of Minnesota Medical School, noted the lack of scientific evidence.
This is, just as with other things, people trying to sell, you know, some magic beans as the solution to a complex problem," Boulware told The Associated Press on Tuesday.
"This would be great if it worked, but I would like to see the data. Venezuela's National Academy of Medicine said it's prudent ... to wait for more data from the carvativir tests according to international protocols.
Since October, Venezuela has been part of trials for the Sputnik V vaccine from Russia, a staunch ally of Maduro's government. Venezuela signed a contract in December with Russia to buy the vaccine, but inoculations aren't scheduled to start until April.
Rosa Colina, 58, said authorities should do more to get Venezuelans vaccinated sooner. She said colleagues at a local health center and some neighbors have died from COVID-19. I'm of the mind that we need the vaccine, not these droplets, she said. I think that won't have any effect.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)